Showing results (941-950 of 1,842) with videos related to

Sort By:
Pageof 185
ESMO Open|May 24, 2025
COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trialsF Rethouze, S Risbourg, C Schiffler, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
ESMO Open|May 22, 2025
Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trialI Meattini, C Becherini, F Martella, et al.
ESMO Open|May 22, 2025
A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancerJ Zhang, R Liu, S Gao, et al.
ESMO Open|May 17, 2025
First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignanciesF Janku, D S P Tan, J Martin-Liberal, et al.
ESMO Open|May 13, 2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II studyE Samalin, L Evesque, A Turpin, et al.
ESMO Open|May 13, 2025
Genomic profiling unlocks new treatment opportunities for ampullary carcinomaC Fabregat-Franco, F Castet, G Castillo, et al.
ESMO Open|May 13, 2025
Landscape of ultra-rare sarcomas: a nationwide study for epidemiology and prognosisE Shimada, M Nakagawa, M Endo, et al.
ESMO Open|June 12, 2025
The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trialsD Hlauschek, C Fesl, M Gnant
ESMO Open|June 11, 2025
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)M Del Re, R Roncato, A Argentiero, et al.
Pageof 185